Rauchhaus M, Doehner W, Francis D P, Davos C, Kemp M, Liebenthal C, Niebauer J, Hooper J, Volk H D, Coats A J, Anker S D
Clinical Cardiology, National Heart and Lung Institute, Royal Brompton Hospital, London, UK.
Circulation. 2000 Dec 19;102(25):3060-7. doi: 10.1161/01.cir.102.25.3060.
Inflammatory immune activation is an important feature in chronic heart failure (CHF). Little is known about the prognostic importance of tumor necrosis factor-alpha (TNF-alpha), soluble TNF-receptor 1 and 2 (sTNF-R1/sTNF-R2), interleukin-6 (IL-6), and soluble CD14 receptors (sCD14) in CHF patients.
In 152 CHF patients (age 61+/-1 years, New York Heart Association [NYHA] class 2.6+/-0.1, peak VO(2) 17.3+/-0.6 mL. kg(-1). min(-1), mean+/-SEM) plasma concentrations of immune variables were prospectively assessed. During a mean follow-up of 34 months (>12 months in all patients), 62 patients (41%) died. Cumulative mortality was 28% at 24 months. In univariate analyses, increased total and trimeric TNF-alpha, sTNF-R1, and sTNF-R2 (all P</=0.0001), sCD14 (P=0.0007), and IL-6 (P=0.005) predicted 24-month mortality. With multivariate analysis and receiver operating characteristics, sTNF-R1 emerged among all cytokine parameters as the strongest and most accurate prognosticator in this CHF population, regardless of follow-up duration and independently of NYHA class, peak VO(2), VE/VCO(2) slope, left ventricular ejection fraction, and wasting (P<0.001). The receiver operating characteristic area under the curve for sTNF-R1 was greater than for sTNF-R2 at 6, 12, and 18 months (all P<0.05).
sTNF-R1 was the strongest and most accurate prognosticator, independent of established markers of CHF severity. Assessment of sTNF-R1 may be useful in identifying patients who are at high risk of death and in monitoring patients undergoing anti-TNF-alpha treatment.
炎症免疫激活是慢性心力衰竭(CHF)的一个重要特征。关于肿瘤坏死因子-α(TNF-α)、可溶性TNF受体1和2(sTNF-R1/sTNF-R2)、白细胞介素-6(IL-6)以及可溶性CD14受体(sCD14)在CHF患者中的预后重要性,目前所知甚少。
对152例CHF患者(年龄61±1岁,纽约心脏协会[NYHA]心功能分级2.6±0.1级,峰值摄氧量[VO₂]17.3±0.6 mL·kg⁻¹·min⁻¹,均值±标准误)的免疫变量血浆浓度进行了前瞻性评估。在平均34个月的随访期内(所有患者均超过12个月),62例患者(41%)死亡。24个月时的累积死亡率为28%。在单因素分析中,总TNF-α和三聚体TNF-α、sTNF-R1、sTNF-R2(均P≤0.0001)、sCD14(P = 0.0007)以及IL-6(P = 0.005)升高可预测24个月死亡率。通过多因素分析和受试者工作特征曲线分析,在所有细胞因子参数中,sTNF-R1是该CHF人群中最强且最准确的预后指标,无论随访时间长短,且独立于NYHA心功能分级、峰值VO₂、VE/VCO₂斜率、左心室射血分数和消瘦情况(P < 0.001)。在6、12和18个月时,sTNF-R1的受试者工作特征曲线下面积大于sTNF-R2(均P < 0.05)。
sTNF-R1是最强且最准确的预后指标,独立于CHF严重程度的既定标志物。评估sTNF-R1可能有助于识别死亡风险高的患者以及监测接受抗TNF-α治疗的患者。